Ian Thomas

CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non-adverse-risk AML: the NCRI AM...

Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML.

Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the U...

Behandeling Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and ...

Lestaurtinib toegevoegd aan eerstelijns chemotherapie bij FLT3-gemuteerde AML: gerandomiseerde studie